Clinical Trial Update: Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical trial evaluated the combination of sunitinib and erlotinib in patients with unresectable or metastatic kidney cancer, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)
• Tarceva (erlotinib)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-02-16